Cargando…

Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma

SIMPLE SUMMARY: A majority of melanoma occurs in people over 65 years. BRAF and MEK inhibitors are standard of care for BRAF mutated metastatic melanoma. The aim of the study was to explore tolerability of targeted therapy in a cohort of patients extracted from a biobank. Patients treated by BRAF an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Becquart, Ondine, Oriano, Bastien, Dalle, Stéphane, Mortier, Laurent, Leccia, Marie Thérèse, Dutriaux, Caroline, Dalac, Sophie, Montaudié, Henri, De Quatrebarbes, Julie, Brunet-Possenti, Florence, Saiag, Philippe, Lesimple, Thierry, Beylot-Barry, Marie, Aubin, Francois, Stoebner, Pierre-Emmanuel, Arnault, Jean-Philippe, Dreno, Brigitte, Porcher, Raphael, Lebbe, Celeste, Guillot, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235702/ https://www.ncbi.nlm.nih.gov/pubmed/34207200 http://dx.doi.org/10.3390/cancers13123042

Ejemplares similares

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France
por: Kandel, Marguerite, et al.
Publicado: (2022)

Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)
por: Russo, David, et al.
Publicado: (2023)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
por: Huynh, Sandra, et al.
Publicado: (2020)

Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study
por: Montaudié, Henri, et al.
Publicado: (2020)

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
por: Mignard, Claire, et al.
Publicado: (2018)

Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database
por: Bassompierre, A., et al.
Publicado: (2021)

La pandémie COVID-19 est associée à des mélanomes diagnostiqués à un stade plus avancé
por: Skowron, F., et al.
Publicado: (2022)

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma
por: Bertrand, Nicolas, et al.
Publicado: (2021)

First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma
por: Le Tourneau, C, et al.
Publicado: (2016)

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
por: Lebbé, Celeste, et al.
Publicado: (2020)

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group
por: Hober, Candice, et al.
Publicado: (2021)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

New Vision in Photoprotection and Photorepair
por: Leccia, Marie-Therese, et al.
Publicado: (2019)

Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy
por: Dousset, Léa, et al.
Publicado: (2021)

Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
por: Valentin, Julie, et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)
por: Nardin, Charlée, et al.
Publicado: (2023)

Prospective external validation of biomarkers to predict acute graft-versus-host disease severity
por: Robin, Marie, et al.
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study
por: Dousset, Léa, et al.
Publicado: (2021)

Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma
por: Boyer, Magali, et al.
Publicado: (2020)

Truncal Acne in Adolescents and Young Adults: Self-reported Perception
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

Online Training on Skin Cancer Diagnosis in Rheumatologists: Results from a Nationwide Randomized Web-Based Survey
por: Viguier, Manuelle, et al.
Publicado: (2015)

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
por: Dupuis, Frantz, et al.
Publicado: (2018)

Impact du confinement lié au COVID-19 sur le retard au diagnostic et la sévérité du mélanome
por: Molinier, Rafaele, et al.
Publicado: (2021)

Interest of corrective makeup in the management of patients in dermatology
por: Seité, S, et al.
Publicado: (2012)

Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
por: Yurchenko, Andrey A., et al.
Publicado: (2022)

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature
por: Grob, Jean-Jacques, et al.
Publicado: (2017)

Que retenir de notre expérience d’enseignement « virtuel » au cours de la période épidémique? Enquête nationale du CEDEF auprès des enseignants et des internes de dermatologie
por: Samimi, Mahtab, et al.
Publicado: (2021)

EMMPRIN Promotes Melanoma Cells Malignant Properties through a HIF-2alpha Mediated Up-Regulation of VEGF-Receptor-2
por: Bougatef, Faten, et al.
Publicado: (2010)

Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy
por: Varin, Juliette, et al.
Publicado: (2020)

Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling
por: Gros, Audrey, et al.
Publicado: (2022)

Solar simulated light exposure alters metabolization and genotoxicity induced by benzo[a]pyrene in human skin
por: von Koschembahr, Anne, et al.
Publicado: (2018)

Blockchain protocols in clinical trials: Transparency and traceability of consent
por: Benchoufi, Mehdi, et al.
Publicado: (2018)

Quaternary low-temperature serpentinization and carbonation in the New Caledonia ophiolite
por: Corre, Marianna, et al.
Publicado: (2023)

The French Observational Cohort of Usual Smokers (FOCUS) cohort: French smokers perceptions and attitudes towards smoking cessation
por: Aubin, Henri-Jean, et al.
Publicado: (2010)

CAARS: comparative assembly and annotation of RNA-Seq data
por: Rey, Carine, et al.
Publicado: (2019)

GOLGI ORIGIN OF TUBULAR INCLUSIONS IN ENDOTHELIAL CELLS
por: Sengel, A., et al.
Publicado: (1970)

Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case
por: Giraud, Violaine, et al.
Publicado: (2015)

Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity
por: Poglio, Sandrine, et al.
Publicado: (2020)

Melanoma hijacks plasmacytoid dendritic cells to promote its own progression
por: Aspord, Caroline, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_41pb3a1n6go5u2sqvfnqa2ts2n